Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Benitec Biopharma Limited (BNTC) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.Benitec Biopharma Limited is a member of the Medical sector. This group includes 1001 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average ...

Core Viewpoint - Benitec Biopharma Limited (BNTC) shows significant upside potential with a mean price target of $25.71, indicating an 85% increase from the current price of $13.90 [1] Price Targets - The average of seven short-term price targets ranges from a low of $17 to a high of $35, with a standard deviation of $6.70, suggesting variability in analyst estimates [2] - The lowest estimate indicates a 22.3% increase, while the highest suggests a 151.8% upside [2] Analyst Consensus - Strong agreement among analysts regarding BNTC's ability to report better earnings than previously predicted supports the potential for stock upside [4] - The Zacks Consensus Estimate for the current year has increased by 0.7% over the past month, with one estimate rising and no negative revisions [12] Zacks Rank - BNTC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Earnings Estimate Revisions - Analysts' optimism regarding BNTC's earnings prospects, reflected in the upward revisions of EPS estimates, correlates strongly with near-term stock price movements [11]

Benitec Biopharma Limited (BNTC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual investo ...

HAYWARD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") "Silence and Replace" platform, today announced the pricing of its underwritten offering of 1,443,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and a concurrent registered direct ...

HAYWARD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) “Silence and Replace” platform, today announced the pricing of its underwritten offering of 1,443,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and a concurrent registered direct ...

-Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 1- -Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 2, with Subject 2 Achieving a Clinically Normal Swallowing Profile Following the Significant Reduction in Total Dysphagic Symptom Burden- -Clinically Significant Improvements in Swallowing Function Achieved 3-months Post-Treatment with BB-301 for Subject ...

Core Insights - Benitec Biopharma Inc. has reported durable and clinically significant improvements in swallowing function for subjects treated with BB-301, a gene therapy for Oculopharyngeal Muscular Dystrophy (OPMD) [1][3][19] - The interim clinical study results will be presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference, highlighting the efficacy of BB-301 in reducing dysphagic symptom burden [1][2] Summary of Clinical Results - Subject 1 showed a 37% reduction in Total Pharyngeal Residue for Thin Liquid, an 18% reduction for Solid Food, and a 29% reduction for Thick Liquids, with a 41% reduction in total dysphagic symptom burden 12 months post-treatment [8][9] - Subject 2 experienced a significant reduction in pathologic sequential swallows, achieving a clinically normal swallowing profile with a 91% reduction in total dysphagic symptom burden, resulting in an SSQ score of 68 units [10][12] - Subject 3 achieved complete resolution of pathologic sequential swallows and a 68% reduction in total dysphagic symptom burden, with an SSQ score of 70 units indicative of a clinically normal swallowing profile at 3 months post-treatment [13][15] Study Design and Methodology - The study is a Phase 1b/2a, open-label, dose escalation trial assessing the safety and clinical activity of BB-301 in OPMD patients [3][19] - Key assessment methods include videofluoroscopic swallowing study (VFSS) for swallowing efficiency and effectiveness, and the Sydney Swallow Questionnaire (SSQ) for patient-reported outcomes [2][5] Company Overview - Benitec Biopharma Inc. is focused on developing novel genetic medicines using its proprietary "Silence and Replace" DNA-directed RNA interference platform, targeting chronic and life-threatening conditions like OPMD [19]

Core Viewpoint - Benitec Biopharma Inc. is actively participating in several upcoming healthcare conferences to showcase its advancements in gene therapy and its proprietary "Silence and Replace" platform [1][2][3]. Group 1: Company Overview - Benitec Biopharma Inc. is a clinical-stage biotechnology company based in Hayward, California, focused on developing novel genetic medicines [4]. - The company utilizes a proprietary "Silence and Replace" DNA-directed RNA interference platform that combines RNA interference with gene therapy [4]. - Benitec is developing therapeutics targeting chronic and life-threatening conditions, including Oculopharyngeal Muscular Dystrophy (OPMD) [4]. Group 2: Upcoming Conferences - Benitec will present at the TD Cowen 45 Annual Health Care Conference on March 5, 2025, from 9:50 AM to 10:20 AM EST, with a format of presentation and 1x1 meetings [2]. - The company will also participate in the Leerink Partners Global Healthcare Conference on March 12, 2025, from 9:20 AM to 9:50 AM EST, featuring a fireside chat and 1x1 meetings [2]. - Additionally, Benitec will be involved in the 2025 Muscular Dystrophy Association Clinical & Scientific Conference, with a panel discussion on March 18, 2025, and a presentation on March 19, 2025 [3].

Core Viewpoint - Benitec Biopharma Limited (BNTC) shows significant upside potential with a mean price target of $25.43, indicating a 127.3% increase from its current price of $11.19 [1] Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $7.02, suggesting variability among analysts [2] - The lowest price target of $17 indicates a 51.9% increase, while the highest target of $35 suggests a potential surge of 212.8% [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [7] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about BNTC's earnings prospects, with a strong consensus in revising EPS estimates higher [9] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 58.8%, with three estimates moving higher and no negative revisions [10] - BNTC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [11] Caution on Price Targets - Solely relying on price targets for investment decisions may not be wise, as empirical research indicates that they often mislead investors [5][8] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [6]

Core Viewpoint - The article emphasizes the importance of identifying and maintaining trends in short-term investing, highlighting that sound fundamentals and positive earnings estimates are crucial for sustaining momentum in stocks [1]. Group 1: Stock Analysis - Benitec Biopharma Limited (BNTC) has shown a solid price increase of 15% over the past 12 weeks, indicating strong investor interest [3]. - The stock has also increased by 4.7% in the last four weeks, suggesting that the upward trend is still intact [4]. - BNTC is currently trading at 80.1% of its 52-week high-low range, indicating a potential breakout opportunity [4]. Group 2: Fundamental Strength - BNTC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [5]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [6]. Group 3: Investment Strategy - The "Recent Price Strength" screen is a useful tool for identifying stocks with strong fundamentals that can maintain their upward trends [2]. - In addition to BNTC, there are several other stocks that meet the criteria of the "Recent Price Strength" screen, suggesting potential investment opportunities [7].